Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Parkinson’s Disease Treatment Market size was over USD 6.8 billion in 2024 and is estimated to reach USD 16.2 billion by the end of 2037, expanding at a CAGR of 7.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of Parkinson’s disease treatment is evaluated at USD 7.3 billion.
As per a report by WHO, more than 3 billion individuals worldwide lived with a neurological illness in 2021. As global life expectancy rises, the geriatric population increases, leading to a higher prevalence of Parkinson’s disease. Countries with aging populations, such as Japan and parts of Europe, are experiencing a surge in such cases, driving the demand for advanced therapeutics. This growing patient base fuels the Parkinson’s disease treatment market by increasing the need for innovative drugs, personalized treatments, and medical interventions to manage symptoms and improve patient’s quality of life.
Furthermore, continuous research has led to advanced drug formulation, including extended-release and combination therapies, improving symptom management, and expanding treatment options. Innovations in gene therapy and stem cell treatments further enhance ailment care, driving market escalation. The Indian Ministry of Science and Technology declared in January 2025 that scientists have created a tailored nanoformulation. The hormone 17β-Estradiol, which is crucial for the treatment of Parkinson's disease (PD), can be released more steadily with the help of this novel formulation. Public awareness and healthcare initiatives foster early diagnosis, improving treatment effectiveness and driving growth in the market.
Parkinson’s Disease Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Rising prevalence of neurodegenerative disorders: The increasing prevalence of Parkinson’s disease and other neurological disorders, driven by genetic predisposition and environmental factors such as pollution and pesticide exposure, is expanding the patient population. More than 300 million people worldwide suffer from uncommon diseases, many of which primarily manifest as neurological symptoms, according to the American Academy of Neurology in January 2025. As more individuals are diagnosed, the demand for advanced therapeutics rises. Ongoing research and drug development, including gene therapy and neuroprotective medications, are driving growth in the Parkinson’s disease treatment market to meet the rising demand for effective care solutions.
- Innovations in emerging treatments: Advancing therapies such as deep brain stimulation (DBS) and precision medicine are revolutionizing Parkinson’s disease treatment by offering more personalized and effective solutions. DBS helps manage motor symptoms, reducing dependency on medications, while personalized medication tailors’ treatments based on genetic and clinical data. Additionally, wearable devices enable real-time symptom tracking, improving disease management and treatment adjustments. These developments drive demand for innovative therapeutics, propelling the surge of the Parkinson’s disease treatment market by enhancing patient outcomes.
Challenges
- Complexity of disease progression: The disease progression varies significantly among patients and is influenced by genetic, environmental, and lifestyle factors. This unpredictability makes it challenging to develop a universal treatment that effectively addresses all cases. As a result, clinical trials face difficulties in standardizing patient groups, leading to inconsistent outcomes and delays in drug approvals. This complexity hinders the development of new therapeutics, increasing the demand for personalized medicine and precision-based treatments, ultimately impacting the growth of the Parkinson’s disease treatment market.
- Challenges in drug delivery systems: The blood-brain barrier (BBB) acts as a protective shield, restricting harmful substances from entering the brain but also limiting the effectiveness of Parkinson’s disease drugs. Many therapeutics struggle to reach affected neurons in sufficient concentrations, reducing their impact. Scientists are exploring novel drug delivery methods, such as nanoparticle-based carriers, intranasal delivery, and gene therapy. However, these approaches require extensive research and regulatory approval, making drug penetration through the BBB a major challenge in Parkinson’s treatment development.
Parkinson’s Disease Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.5% |
|
Base Year Market Size (2024) |
USD 6.8 billion |
|
Forecast Year Market Size (2037) |
USD 16.2 billion |
|
Regional Scope |
|
Parkinson’s Disease Treatment Segmentation
Drug Class (Levodopa/Carbidopa, Dopamine Agonists, Adenosine A2A Antagonist, COMT Inhibitors, MAO-B Inhibitors, Glutamate Antagonist, Others)
The levodopa/carbidopa segment is likely to hold Parkinson’s disease treatment market share of more than 53.2% by 2037. The segment's growth is primarily due to its proven effectiveness in managing Parkinson's disease motor symptoms. The combination of levodopa, which replenishes brain dopamine levels, and carbidopa, which ensures levodopa reaches the brain intact, provides significant relief. In September 2024, Amneal Pharmaceuticals introduced CREXONT capsules, which feature an innovative formulation of carbidopa/levodopa that combines immediate-release granules and extended-release pellets. This advancement, along with continued usage of such treatments, plays a vital role in driving the growth of the market.
Patient (Adult, Pediatric)
Based on patients, the adult segment is poised to garner the majority of Parkinson’s disease treatment market share over the forecast period. The segment is growing due to the increasing prevalence of the disease among the aging population. Parkinson’s disease primarily affects individuals over 60, and as life expectancy rises globally, the number of adult patients is increasing. Additionally, adults are more likely to receive timely diagnoses and treatment, which boosts the demand for effective therapeutics. Advances in treatment options tailored to adult patients further contribute to the segment’s development.
Stratified estimates of PD prevalence based on age in China (2024)
|
Age Group |
Sample Size |
PD Prevalence (%) |
|
45-49 |
1,833 |
0.05 |
|
>80 |
985 |
2.85 |
Source: NLM
Our in-depth analysis of the global parkinson’s disease treatment market includes the following segments:
|
Drug Class |
|
|
Patient |
|
|
Route of Administration |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportParkinson’s Disease Treatment Industry - Regional Synopsis
North America Market Statistics
North America Parkinson’s disease treatment market is likely to hold revenue share of more than 35.1% by 2037. The market in the region is expanding due to a growing pipeline of drugs undergoing clinical trials, with many receiving FDA approvals. Regulatory support accelerates innovation, bringing new treatment options to patients. Additionally, the integration of telemedicine and remote monitoring tools enhances access to specialist care, improving disease management and treatment adherence. These advancements collectively drive market growth by ensuring timely interventions, increasing patient engagement, and fostering the continuous development of more effective Parkinson’s disease therapies.
In the U.S., the Parkinson's disease treatment market is expanding due to a rising number of cases, primarily driven by an aging population and increased life expectancy. According to a 2022 study supported by the Parkinson's Foundation, approximately 90,000 Americans receive a Parkinson's disease diagnosis each year. As more individuals are diagnosed, the demand for advanced treatments grows. Pharmaceutical companies are actively developing improved therapies, including extended-release formulation, combination drugs, and gene therapy. These innovations enhance symptom control, improve patient outcomes, and drive market growth by offering more effective and targeted treatment options for managing Parkinson’s disease.
Canada is leading in genetic research and precision medicine, advancing personalized Parkinson’s treatments through biomarker-based therapies and individualized drug regimes. These innovations enhance treatment effectiveness, improving patient outcomes. Additionally, advanced technologies such as Deep Brain Stimulation (DBS) and non-invasive neuromodulation are gaining traction, offering new options for patients with advanced Parkinson’s. The integration of these cutting-edge approaches expands therapeutic choices, driving the growth of the Parkinson’s disease treatment market in Canada by improving disease management and patient care.
Europe Market Analysis
Europe is a hub for parkinson’s disease clinical trials, with pharmaceutical companies and research institutions collaborating to develop disease-modifying therapies. Also, digital health solutions such as AI-driven diagnostics, telemedicine consultations, and wearable monitoring devices are enhancing disease management by improving specialist access and real-time symptom tracking. For instance, in January 2025, Medtronic launched BrainSense technology, which is revolutionizing Parkinson's disease treatment in Europe with personalized deep brain stimulation and innovative programming capabilities. Together, these advancements fuel the growth of Europe’s Parkinson’s disease treatment market by expanding treatment options and optimizing patient care.
The Parkinson’s disease treatment market in Germany is poised for growth, bolstered by its strong healthcare system and rising demand for effective neurological treatments. Increasingly, therapies are being adopted to manage motor symptoms and enhance patients' quality of life, with a focus on evidence-based practices. Regulatory support and advancements in formulation technologies further contribute to market development, while ongoing efforts to improve patient access through enhanced healthcare infrastructure will continue to drive expansion in this vital sector.
The UK Parkinson’s disease treatment market is poised for substantial growth, driven by heightened awareness of neurological health and advanced treatment options. In July 2024, Parkinson's UK provided USD 15.0 million through its Virtual Biotech program to test a potential treatment called MTX325 for individuals with Parkinson's disease. The National Health Service (NHS) has incorporated these treatments into patient care plans, improving accessibility for those affected by the condition. Additionally, innovative formulations from UK pharmaceutical companies are enhancing the effectiveness of these treatments. Further, government initiatives aimed at public health and the availability of advanced neurodegenerative medications are expanding the Parkinson’s disease treatment market.
Companies Dominating the Parkinson’s Disease Treatment Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Olatec Therapeutics
- Biotech Ltd
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- GlaxoSmithKline plc. (GSK)
- AbbVie, Inc.
- Acorda Therapeutics, Inc.
- Bayer AG
- IRLAB Therapeutics AB
- Amneal Pharmaceuticals LLC
- Supernus Pharmaceuticals, Inc.
Key companies in the Parkinson’s disease therapeutic market are driving innovation through advanced drug formulations, gene therapy, and neuroprotective treatments. They are developing extended-release medications for better symptom control and investing in disease-modifying therapies to slow disease progression. Additionally, companies are exploring deep brain stimulation (DBS) advancements and leveraging AI for personalized treatment approaches. Research in stem cell therapy and novel drug delivery systems, such as nanoparticle-based solutions, is further revolutionizing the market, improving patient outcomes, and expanding treatment options. Some of the key companies are:
In the News
- In January 2025, Bayer AG and BlueRock Therapeutics LP announced Bemdaneprocel, through the exPDite-2 trial, innovates Parkinson's disease treatment by advancing allogeneic cell-based therapies, potentially offering new hope and improved treatment options for those affected by this neurodegenerative disorder.
- In January 2025, IRLAB Therapeutics AB introduced the promising development of IRL757, which enhances the Parkinson's disease treatment market by potentially offering safer, effective treatment options for older adults, advancing patient care and quality of life.
Author Credits: Radhika Pawar
- Report ID: 7204
- Published Date: Feb 20, 2025
- Report Format: PDF, PPT
